The DOI matches its Crossref record.
Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case–Control Study
Abstract
OBJECTIVES: Azathioprine is an accepted treatment of inflammatory bowel disease (IBD), but concerns exist regarding its carcinogenic potential. Studies in renal transplant and rheumatology patients have reported an increased cancer risk. In IBD, studies suggest a small increased risk of lymphoma and protection against colorectal cancer, but the overall risk of malignancy has not been established. METHODS: We conducted a nested case-control study using the General Practice Research Database. Records of IBD patients were examined for azathioprine prescriptions and cancers. Prescriptions per year of follow-up were grouped for analysis. Azathioprine use was compared between IBD cases (with a diagnosed cancer) and IBD controls (without). RESULTS: Overall, 15,471 patients with IBD and over 1 year of appropriate data were identified. Among these, 392 developed cancer, of whom 10.5% received at least one prescription for azathioprine, compared with 1,914 (12.7%) of the controls. Analyzing the occurrence of any cancer against azathioprine prescription showed a nonsignificant protective effect (odds ratio (OR)=0.92, 95% confidence interval (CI)=0.79-1.06). Correction for the effects of age and smoking removed this effect (OR=1.04, 95% CI=0.89-1.21). Diagnosis of lymphoma was associated with ever use of azathioprine with OR of 3.22, CI=1.01-10.18. CONCLUSIONS: We found evidence of an increased risk of lymphoma, which is consistent with previous studies. We found no overall increase in risk of cancer in individuals with IBD who had taken azathioprine. Our study does not show a need for azathioprine cessation in the medium term in IBD because of the risk of malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The burden of inflammatory bowel disease in Europe
Burisch, J., Jess, T., Martinato, M., & Lakatos, P. L. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.01.010 · Cited by 961
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Annese, V., Beaugerie, L., Egan, L., Biancone, L., Bolling, C., Brandts, C., Dierickx, D., Dummer, R., Fiorino, G., Gornet, J. M., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv141 · Cited by 428
Kotlyar, D. S., Lewis, J. D., Beaugerie, L., Tierney, A., Brensinger, C. M., Gisbert, J. P., Loftus, E. V., Peyrin-Biroulet, L., Blonski, W. C., Van Domselaar, M., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.05.015 · Cited by 414
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Gordon, H., Biancone, L., Fiorino, G., Katsanos, K. H., Kopylov, U., Al Sulais, E., Axelrad, J. E., Balendran, K., Burisch, J., de Ridder, L., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac187 · Cited by 317
Ungar, B., Kopylov, U., Engel, T., Yavzori, M., Fudim, E., Picard, O., Lang, A., Williet, N., Paul, S., Chowers, Y., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13862 · Cited by 118
Metadata
- Authors
- Armstrong, R. G., West, J., & Card, T. R.
- Venue
- American Journal of Gastroenterology
- Published
- 2010-07
- Volume
- 105
- Issue
- 7
- Pages
- 1604-1609
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2048717004
- Cited by
- 158
- References
- 0
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case–Control Study. https://app.cochat.ai/papers/10.1038/ajg.2009.745
- The paper
- Armstrong, R. G., West, J., & Card, T. R. (2010). Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case–Control Study. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2009.745
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.